specialti chemic gase rate downgrad unit state go sg websit
troubl doubl
sell buy
upsid tp
nc chang
investor alreadi overli happi frutarom acquisit
like overpaid compar riski asset ev/ebitda although
impli ev/ebitda dupont nutrit bioscienc
seem moder closer inspect look high given
acquir sale gener non-cor bulki busi soy
protein biocid sweeten clean technolog sinc probabl
still busi integr frutarom ad equat might easili
overstretch compani tri investor patienc still
wait reap benefit frutarom given greater risk rais
discount appli peer-bas valuat reduc
tp downgrad rate buy sell
might overstretch recent may acquir isra
frutarom ev/ebitda sinc deal close sept legaci
frutarom disappoint organ growth term face briberi
investig frutarom russia ukrain unit frutarom made string
acquisit acquir like yet fulli integr
think must still busi integr frutarom legaci deal ad
mix dupont nutrit bioscienc busi slightli bigger
although appear well run cultur clash look unlik deliv
synergi target could result friction sg initi comment
overpay think add sever attract busi
probiot cultur enzym ex danisco come catch
chemic sweeten soy protein biocid process ingredi account
 sale strip inflat acquisit multipl least
special implicitli pay high price hefti acquisit
wait see mode
expect deal close
visibl qualiti acquir busi like limit
much need portfolio prune wait ditto deliveri cost sale
synergi given difficulti encount sinc acquir frutarom
on-going carve-out process dupont reduc visibl increas risk like
weigh stock result rais valuat discount
updat peer group sotp point fair valu
project tsr lack visibl fundament cut rate buy sell
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
morri trust structur preserv balanc sheet
sunday night decemb announc merger dupont nutrit
bioscienc unit link transact valu dupont ev/ebitda set
revers morri trust dupont sharehold keep major stake newco
proce deal tax free lead oper
need leverag balanc sheet get acquisit done dupont
receiv one-tim special cash payment specif time point determin
deal expect close jan accord major sharehold winder
share declar support deal expect net debt/ebitda peak
transact close declin two year compani
intend keep invest grade rate
uniqu ingredi power hous
see good strateg rational deal virtual overlap flavour
fragranc hous dupont nutrit pharma ingredi produc
deal creat uniqu global lead ingredi powerhous high qualiti portfolio
broad diversif across attract nutrit cosmet pharma market
impli ev
dupont margin bigger sale approxim
ebitda ebitda margin slightli deal
result sale cost synergi end third year post
close result upsid newco margin target
addit newco target sale synergi
extend portfolio probiot cultur textur system aim
becom one-stop shop solut provid nutrit cosmetics/deterg
ingredi market see potenti newco could outperform peer
long term howev long-term potenti come signific oper integr
risk although attract paper sale synergi need deliv first
carve-out dupont still on-going close expect investor must
prepar wait
 nutrit ingredi
dupont nutrit bioscienc segment creat seri acquisit
made chemic dupont past decad deal includ danisco
acquir dupont ev/ebitda dsm stake
back bid view valuat time nutrit
unit pick also integr former sola joint ventur
pharma food microbi control busi
result diversifi portfolio includ food ingredi industri
enzym estim bioscienc repres sale nutrit
howev within portfolio identifi bycatch make sale think
look divest busi medium long term exit
multipl non-cor busi like significantli
ev/ebitda paid entir busi estim best
microbi control gener sale although seem decent
busi fit specialti ingredi portfolio view lanxess acquir similar
biocid busi ev/ebitda
protein solut compris sale backbon busi soy
protein although acknowledg hyper pure protein categori
attract soy protein rather commoditis consum focu view
symris acquir egg meat protein specialist adf/edf ev/ebitda
think soy protein trade discount
emulsifi sweeten repres sale backbon busi
chemic sweeten d-xylos xylitol lactitol direct proxi sweeten
market tate lyle uk consid sugar sweeten compani tate
lyle trade ev/ebitda
clean technolog account sale busi focus industri
enzym includ sulfur acid product regener technolog hydroprocess
technolog desulfuris motor fuel alkyl technolog product clean
high octan gasolin air qualiti control system fcc flue ga scrub refineri
scrub applic comprehens suit aftermarket servic solut
offer see direct peer would includ busi specialti
chemic comparison basket ashland exampl trade ev/ebitda
strip less attract bulki busi estim pay
ev/ebitda specialti busi high price believ medium
term like streamlin acquir portfolio
nutrit bioscienc revenu split product line
given fact acquisit dupont busi set close
expect anti-trust issu dupont first busi fulli integr
frutarom deliv integr synergi carv busi dupont
prepar integr process see signific risk
disappoint next year manag distract core
busi group alreadi sever chang mode visibl
underli perform like remain low consequ adjust peer group
non-cor exposur reflect chang mix describ
increas peer valuat discount reflect increas
execut risk next month averag ev/ebita price-to-earnings fair valu
peer sotp indic fair valu per share vs
sotp indic fair valu driven higher risk premium post announc
acquisit dupont busi
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
share basic year end/outstand
share price average hist yr current
report complet dec cet
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report thoma swoboda
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
valu per share base sotp model averag ev/ebita price-to-earnings fair valu peer sotp indic
fair valu per share vs appli valuat discount european peer group ev/ebitda
earn multipl due histor slower top line growth higher earn volatil well risk aris
integr dupont busi
upsid signific acceler underli growth legaci dupont busi potenti impact tp
high visibl earn integr effort ahead close dupont acquisit potenti impact tp earli exit
non-cor busi attract multipl soy protein sweeten biocid clean technolog potenti impact tp
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
equiti rate dispers relationship
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
